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In this paper, initial work on MSH at Dr. Lerner's laboratory in Portland, Oregon, from 1952
to 1954 is presented. Thedevelopment ofan in vitrobioassay method enabled us toshow increased
urinary excretion ofMSH in Addison's disease. TheabilityofMSH toincreaseskin pigmentation
in man was alsodemonstrated. Subsequent workon MSH during thepast thirty yearsis reviewed,
such as characterization of a- and fl-MSH and their precursors in the pituitary gland and
localization ofMSH-like peptides in various regions ofthe brain.
Finally there are presented the characterization of -y-MSH, the hypothermic effect of
intracisternal administration of'y-MSH, the effect ofcorticortropin releasing factor on increased
secretion of a-MSH from rat pituitary, and the effect of arginine vasopressin on secretion of
a-MSH from pituitary adenoma.
It is a great honor and pleasure for me to participate in the Aaron B. Lerner
symposium, honoring his thirty years of dedication and accomplishment at Yale
University.
From 1952 to 1954 I worked with him on MSH in Portland, Oregon, before he
moved to this university in 1955. During the three decades after I left Dr. Lerner's
laboratory, remarkable progress has been made on MSH. In this paper I will first
introduce our research on MSH at Lerner's laboratory in Portland, Oregon, from 1952
to 1954 and will then review some ofthe work on MSH during the past 30 years.
While I was working as a fellow in the department ofmedicine at the University of
Kansas Medical Center in 1951, several patients were observed whose skin pigmenta-
tion increased noticeably after ACTH therapy. This was explained in an article by
Lerner and Fitzpatrick, entitled "Biochemistry of Melanin Formation," [1], which
reported that a patient receiving ACTH developed marked pigmentation of the skin.
The ACTH preparation contained appreciable MSH, a finding which may be relevant
to the development of pigmentation. The content of melanophore hormone in human
pituitary was demonstrated elsewhere [2]. I wrote Drs. Lerner and Fitzpatrick at Ann
Arbor, Michigan, discussing this problem. This event began my association with Dr.
Lerner, and, in September 1952, we started our work on MSH in Portland, Oregon.
First an in vitro quantitative method was developed [3] for measuring MSH, using
the change of light reflection from frog skin before and after immersion in solutions
containing MSH. The change in light reflection was measured by a photoelectric
reflection meter.
We showed that this method could be used to determine MSH in body fluids and
tissue extracts [4]. We measured MSH in blood and urine and showed that it is
increased in patients with Addison's disease [4]. We also administered hog MSH
preparation to five men and two women and observed increased pigmentation in all of
them [5].
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ACTH H-Ser-Tyr-S.r-Met-G1u-Ws-Phe-Aro-Trn-GtrLys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-VaI -Lys-Val
a-MSH CH3CO-So-Tyr-Ser-Met-GIu-His-Phe-Ar-Trp-GIY-tys4io-VW - NH2 Tyr
Pro
HO-Pho-Glu-Leu-Pro-Phe-Ala-Glu-AIa-S.r-Glu-Asp-Glu-Ala-Gly-Asn
FIG. 1. The structures ofhuman ACTH and a-MSH.
Lerner and Lee isolated a-MSH from porcine pituitary in 1955 [6]. Its primary
structure was subsequently determined by Harris and Lerner in 1957 [7]. This peptide
was later found and chemically identified in pituitaries from other species, including
the cow, sheep, horse, macaque, camel, and dogfish [8]. a-MSH is a thirteen amino
acid residue peptide, as shown in Fig. 1. Because its structure is identical with the
N-terminal tridecapeptide sequence of ACTH, it was considered that a-MSH might
be derived from ACTH.
Another MSH, fl-MSH, was also isolated from porcine pituitary glands in 1956 by
Geschwind et al. [9] and its amino acid sequence was determined the next year [10].
Later it was determined that the amino acid sequence of fl-MSH corresponds to
fl-lipotropin (f3-LPH) (41-58) [11]. The amino acid sequence of ,B-endorphin, which
was isolated in 1975, also corresponds to the C-terminal portion (61-91) of ,-LPH,
(Fig. 2), and so it was speculated that ,B-MSH and f3-endorphin are derived from
f3-LPH [12].
In 1977, Mains, Eipper, and Ling [13] disclosed that ACTH and 3-endorphin are
derived from a 31 K common precursor. In their series ofstudies on the biosynthesis of
the ACTH/,B-endorphin precursor in the anterior and intermediate lobes of rat
pituitary, they demonstrated that post-translational processing of the 31 K common
precursor is different between anterior and intermediate lobes. As shown in Fig. 3, in
the anterior lobe the 31 K common precursor consists ofa 16 K fragment, and ACTH
and f,-LPH sequences. It was also found that ACTH and ,B-LPH are the main
products, along with small amounts of 'y-LPH and f,-endorphin in the anterior lobe,
whereas in the intermediate lobe a-MSH, corticotropin-like intermediate lobe peptide
(CLIP), fl-MSH, and ,B-endorphin are the predominant final peptides.
In 1979, Nakanishi and his co-workers characterized the complete sequence of the
mRNA isolated from the intermediate lobe ofbovine pituitary, which codes for the 31
K precursor ofACTH/fl-lipotropin by using techniques of DNA cloning and nucleo-
tide sequence analysis (Fig. 4) [14]. They found in the precursor an amino acid
sequence which is strikingly similar to the sequence of a-MSH and g-MSH, and
named the sequence y-MSH. According to the mRNA sequence, the nucleotide
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FIG. 2. The structures ofjl-MSH, ,3-endorphin, andj3-LPH.
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FIG. 3. Proteolytic processing ofthe 31 K precursor in the pituitary.
sequences encoding the common amino acids are conserved except for a very few
changes.
In 1978, Shibasaki et al. isolated y-MSH from bovine pituitary extracts. They
developed radioimmunoassays for two possible y-MSHs which were synthesized
according to the sequence ofthe precursor molecule, y,-MSH and 73-MSH, as shown
in Fig. 5 [15,16].
According to the results (Fig. 6), there are two 73-MSH-like peptides in bovine
pituitary: one slightly smaller than fl-LPH and the other with almost the same
molecular size as that of ACTH. "Small" 'y3-MSH was found to be a glycosylated
Lys-'Y3-MSH [17,18]. "Big" 'Y3-MSH is dominant in the anterior pituitary but both
'Y3-MSHs have almost the same distribution in the intermediate lobe. In addition to
y3-MSH, Lys--y,-MSH and related "big" y,-MSH exist in the intermediate lobe
extract ofbovine pituitary [16,19]. Therefore, in theanterior pituitary, "big"'y3-MSH,
ACTH, and fl-LPH are predominant. On the other hand, in the intermediate lobe,
each peptide is further processed into smaller ones such as "small" Y3-MSH plus
Lys-,y1-MSH, a-MSH plus CLIP, and g-endorphin plusf3-MSH, respectively.
r-MSH ACTH R-LPH
a-MSH 8-MSH
4 10
a-MSH Met-Glu-His-Phe-Arg-Trp-Gly
T 13
i-MSH Met-Glu-His-Phe-Arg-Trp-Gly
-S3 -47
r-MSH Met-Gly-His-Phe-Arg-Trp-Asp
FIG. 4. The structure ofACTH-f,-LPH precursor.
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FIG. 5. Possible y-MSHs.
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Y3-MSH-positive neurons are found in hypothalamus, and their positive fibers are
widely distributed in the brain [20].
A rat which has been intraventricularly or intracisternally injected with synthetic
TY3-MSH shows transient behavioral hyperactivity, cortical desynchronization, and
hypothermia [21]. As shown in Fig. 7, Shibasaki demonstrated that intracisternal
administration of 10 ,ug synthetic Y3-MSH significantly lowered core temperature by
1.250C, 30 minutes after injection into rats at room temperature. This action of
'Y3-MSH was more manifest when the experiment was performed at 40C. The
administration of 100 ng y3-MSH significantly lowered core temperature, and the
effect lasted two hours (Fig. 8).
Recent immunohistochemical studies by several investigators have revealed that
a-MSH-like immunoreactivity is widely distributed not only in the intermediate lobe
ofpituitary but also in various regions ofthe brain [22]. In the brain, a-MSH-positive
neurons exist in the hypothalamus, thalamus, midbrain, and cortex. Nerve fibers with
a-MSH-like immunoreactivity are found in the septum, hypothalamus, amygdala, and
cortex.
a-MSH-positive neurons in the arcuate nucleus are also stained by f-endorphin
antiserum. However, neurons stained by a-MSH antiserum in the subthalamus and
dorsomedial hypothalamic and lateral hypothalamic nuclei are not stained by
f3-endorphin antiserum. The latter a-MSH neuron group is therefore called the
secondary melanotropinergic system [23]. This may imply that each a-MSH neuronal
group has a different role in neurotransmission or neuromodulation in the brain. The
different staining pattern may be due to variation in post-translational processing
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FIG. 9. The effect ofovine CRF on the secretion of IR-a-MSH by
cultured rat neurointermediate lobe cells.
within different branches of the same neuron: a-MSH and f,-endorphin are the final
products in some fiber branches, while a-MSH is the only final product in the
branches. It is also possible that different neurons have specific processing systems
which yield the same single or multiple final products at every secretory site in the
neuron. Diacetyl a-MSH, in addition to authentic acetylated a-MSH, exists in the
intermediate lobeofthe pituitary [24]. On theother hand, theacetylation ofa-MSH in
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FIG. 10. The effect of dopamine on
the secretion ofIR-a-MSH by cultured
neurointermediate lobe cells.
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FIG. 11. The effect ofovine CRF on the release of IR-a-MSH by rat fetus pituitary obtained
on day 16.5 ofgestation.
brain is a controversial issue [25,26]. Some groups have provided evidence for the
presence of authentic acetylated a-MSH in extracts of rat brain tissue; however, the
presence ofdes-acetyl a-MSH instead ofauthentic a-MSH has also been reported.
In peripheral tissues, a-MSH-like immunoreactivity is present in both mucosal and
muscular layers in all areas of the gastrointestinal tract [27]. The highest concentra-
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tions were found in the duodenum. This fact may suggest that a-MSH is involved in
digestion and absorption offood in the gastrointestinal tract.
Shibasaki has shown that the secretion ofa-MSH is stimulated by CRF in rat and
inhibited by dopamine. Figure 9 shows that synthetic ovine CRF stimulates the
secretion of a-MSH from monolayer-cultured intermediate lobe cells in a dose-
dependent manner.
Figure 10 shows that dopamine decreases the secretion of a-MSH in a dose-
dependent manner and also attenuates the CRF-induced secretion at a concentration
of 1 x 1 -6 M. Shibasaki and Hotta haverecentlyobserved that, in a perfusion system,
the addition of ovine CRF stimulates secretion of a-MSH from rat fetus pituitary
obtained at 16.5 days ofgestation (Fig. 11). Daikoku et al. have reported that beaded
CRF-positive fibers are observed in the median eminence on day 17.5 of gestation in
the rat [28]. It was therefore concluded that the CRF receptor system in the
intermediate lobe cells ofthe pituitary is already present in advance ofthe appearance
ofthe hypothalamic regulatory mechanism ofCRF.
We found an a-MSH-like substance secreted by cultured pituitary adenoma cells
obtained from patients with Cushing's disease or Nelson's syndrome. Figure 12 shows
the elution profile ofACTH, f3-LPH, and 'Y3-MSH in gel filtration chromatography of
Sephadex G-75 of the culture medium in the upper panel; the elution profile of an
a-MSH-like substance is shown in the lower panel. A peak of a-MSH-like immuno-
reactivity, expressed as closed circles, was found at the position where '251I-authentic
a-MSH eluted.
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Figure 13 shows that the amount of a-MSH secreted into medium from cultured
pituitary adenoma cells causing Nelson's syndrome was increased dose-dependently by
arginine, vasopressin, and VIP. Patients with thesediseases show hyperpigmentation in
skin and mucosa. Therefore, a-MSH-like substance secreted from pituitary adenoma
cells may contribute to the hyperpigmentation in these patients.
In addition to papers on skin darkening, many papers on the action ofa-MSH have
been published, including those on stimulation of sebum secretion and dermal
lipogenesis [29], increase of intrauterine growth in the rat [30], induction of growth
hormone and luteinizing hormone secretion in man [31,32], stimulation ofaldosterone
secretion in the rat [33], and elevation ofplasma glucagon, insulin, and free fatty acid
levels in the rabbit [34]. Furthermore, the entire amino acid sequence of the a-MSH
precursor and its metabolism in the pituitary has been characterized. However, the
physiological roles of a-MSH, especially in the brain and GI tract, are still unknown.
Therefore I look forward tofurther studies on MSH, based upon those which have been
initiated by Dr. Lerner.
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